Table 1.

Comparison of patient characteristics

VariableMSD/MUD; n = 75Haplo; n = 70 (%)
Median patient age, years (range) 49 (22-64) 41 (2-64) 
Age <18, n (%) 0 (0) 14 (20) 
Pre-BMT disease status, n (%)   
 CR 45 (60) 34 (49) 
 MRD 14 (19) 11 (16) 
 Active disease 16 (21) 25 (35) 
HCT-CI, median (range) 2 (0-8) 1 (0-5) 
0-3, n (%) 49 (66) 64 (91) 
≥3, n (%) 16 (21) 6 (9) 
Median donor age: years (range) 41 (17-67) 38 (11-69) 
Female → Male, n (%) 20 (27) 24 (34) 
Recipient CMV positive, n (%) 39 (53) 28 (40) 
CMV mismatch, n (%) 34 (45) 23 (33) 
Cell dose infused, n (range)   
 TNC x 108/kg 3.8 (0.32-8.82) 4.8 (2.63-11.2) 
 CD34+ cells × 106/kg 3.3 (1-9.87) 4.5 (1.77-11.24) 
 CD3+ cells × 107/kg 4.2 (1.5-30.28) 4.78 (1.09-11.7) 
VariableMSD/MUD; n = 75Haplo; n = 70 (%)
Median patient age, years (range) 49 (22-64) 41 (2-64) 
Age <18, n (%) 0 (0) 14 (20) 
Pre-BMT disease status, n (%)   
 CR 45 (60) 34 (49) 
 MRD 14 (19) 11 (16) 
 Active disease 16 (21) 25 (35) 
HCT-CI, median (range) 2 (0-8) 1 (0-5) 
0-3, n (%) 49 (66) 64 (91) 
≥3, n (%) 16 (21) 6 (9) 
Median donor age: years (range) 41 (17-67) 38 (11-69) 
Female → Male, n (%) 20 (27) 24 (34) 
Recipient CMV positive, n (%) 39 (53) 28 (40) 
CMV mismatch, n (%) 34 (45) 23 (33) 
Cell dose infused, n (range)   
 TNC x 108/kg 3.8 (0.32-8.82) 4.8 (2.63-11.2) 
 CD34+ cells × 106/kg 3.3 (1-9.87) 4.5 (1.77-11.24) 
 CD3+ cells × 107/kg 4.2 (1.5-30.28) 4.78 (1.09-11.7) 

CMV, cytomegalovirus; CR, complete remission; haplo-HLA, haploidentical donor; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index; MRD, minimal residual disease; MSD-HLA, matched sibling donor; MUD-HLA, matched unrelated donor; TNC, total nucleated cells.

Close Modal

or Create an Account

Close Modal
Close Modal